

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1.-21. (Cancelled)

22. (Previously Presented) A method of treating vasospasm in a subject needing such treatment comprising the step of:  
topically applying to a region of the subject's tissue requiring treatment of vasospasm an effective amount of a semi-solid composition, the composition comprising:  
a vasoactive prostaglandin;  
a penetration enhancer selected from the group consisting of an alkyl-N-substituted amino) alkanoate, an alkyl-2-(N,N-disubstituted amino) alkanoate, an (N-substituted amino) alkanol alkanoate, an (N,N-disubstituted amino) alkanol alkanoate, a pharmaceutically acceptable salt thereof and a mixture thereof;  
a polymer thickener consisting of shear-thinning polysaccharide gum selected from a guar gum, and a modified guar gum;  
a lipophilic component that is selected from the group consisting of an aliphatic C<sub>1</sub> to C<sub>8</sub> alcohol, an aliphatic C<sub>8</sub> to C<sub>30</sub> ester, a liquid polyol and a mixture thereof; water and  
a buffer system that provides a buffered pH value for said composition in the range of about 3 to about 7.4;

wherein application of the semi-solid composition produces an increase in blood flow through the region of vasospasm within thirty minutes of the application.

23. (Original) The method of claim 22 wherein the tissue is skin.

24. (Withdrawn) The method of claim 22 wherein the tissue is vascular extima.

25. (Original) The method of claim 22 wherein the vasoactive prostaglandin is selected from the group consisting of prostaglandin E<sub>1</sub>, prostaglandin E<sub>2</sub>, a pharmaceutically acceptable salt thereof, a lower alkyl ester thereof and a mixture thereof.

26. (Cancelled)

27. (Original) The method of claim 22 wherein the penetration enhancer is dodecyl 2-(N,N-dimethylamino)-propionate or a pharmaceutically acceptable salt thereof.

28. (Original) The method of claim 22 wherein the lipophilic component comprises at least one aliphatic C<sub>8</sub> to C<sub>30</sub> ester.

29. – 64. (Cancelled)